NVS Phase 3 readout: a positive outcome, +0.5%

On January 29, 2026, Secukinumab 300 mg, s.c. — Novartis AG (Giant Cell Arteritis) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +0.5% in the window around the event. It had already run +10.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.